ARA-290 (Cibinetide)
An EPO-derived peptide that retains the cytoprotective and anti-inflammatory effects of erythropoietin without affecting red blood cell production.
Overview
ARA-290 (also called cibinetide) is a synthetic peptide based on the structure of erythropoietin. It binds the innate repair receptor — distinct from the classical EPO receptor — providing tissue-protective and anti-inflammatory effects without driving erythropoiesis. It has been studied for neuropathic pain (especially in sarcoidosis) and diabetic neuropathy.
Benefits
- Anti-inflammatory and tissue-protective
- May reduce neuropathic pain
- No effect on red blood cell count (unlike EPO)
- Studied for sarcoidosis and diabetic neuropathy
Mechanism of Action
Binds the innate repair receptor (a heterodimer of EPO receptor and beta common receptor), activating tissue protection pathways without erythropoietic signaling.
Dosage (informational only)
- Typical range
- 4–8 mg per day in clinical trials
- Frequency
- Daily subcutaneously
Investigational. Most data comes from sarcoidosis and diabetic neuropathy trials.
Side Effects
- Generally well-tolerated
- Possible injection site reactions
- Mild headache
Related peptides
A pentadecapeptide derived from a gastric protein, widely studied for its regenerative and cytoprotective effects.
A synthetic fragment of Thymosin Beta-4 widely used in injury recovery research and frequently stacked with BPC-157.
A naturally occurring thymic peptide used clinically as an immunomodulator for chronic viral infections and immune support.